{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:24:30Z","timestamp":1790029470388,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA) are thought to develop through two major mechanisms: chronic inflammation and immunosuppression. This study aimed to investigate the relationship between histological subtypes and two representative biomarkers, rheumatoid factor (RF) and Epstein\u2013Barr virus-encoded RNA in situ hybridisation (EBER-ISH), in RA-associated LPD (RA-LPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed patients with clinically diagnosed RA-LPD who underwent tissue biopsy at a single institution. Histological subtypes were classified as classic Hodgkin lymphoma (CHL), monomorphic LPD (Mono-LPD), polymorphic LPD (Poly-LPD), or reactive lymphoid hyperplasia\/normal variant (RLH\/NV). RF levels and EBER-ISH results were compared across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 69 RA-LPD patients were included in the analysis. RF levels differed significantly across the four histological subtypes (P\u2009=\u2009.024), with the highest median level observed in the Mono-LPD group. EBER-ISH positivity differed significantly among the subtypes (P\u2009&amp;lt;\u2009.001), with a significantly higher rate in Poly-LPD compared to Mono-LPD and RLH\/NV. Mono-LPD tended to show high RF titres and EBER-ISH negativity, whereas Poly-LPD and CHL were characterised by low RF titres and high EBER-ISH positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RF and EBER-ISH status differed among histological subtypes of RA-LPD, and their combined assessment may help explain its histological diversity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf125","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T13:11:31Z","timestamp":1765458691000},"page":"543-549","source":"Crossref","is-referenced-by-count":1,"title":["Histological subtypes of rheumatoid arthritis-associated lymphoproliferative disorders: Serological and Epstein\u2013Barr virus findings"],"prefix":"10.1093","volume":"36","author":[{"given":"Keiichiro","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1455-6822","authenticated-orcid":false,"given":"Ryuichi Minoda","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara ,","place":["Japan"]},{"name":"Department of Transformative Analysis for Human Specimen, Graduate School of Medicine, The University of Osaka , Osaka ,","place":["Japan"]},{"name":"Department of Infection Control, Graduate School of Medicine, The University of Osaka , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Akebo","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara ,","place":["Japan"]},{"name":"Department of Palliative Medicine, National Cancer Center Hospital East , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Tenri Hospital , Nara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Tenri Hospital , Nara ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026070605221782000_ref1","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026070605221782000_ref2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"key":"2026070605221782000_ref3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208105","article-title":"How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries","volume":"75","author":"Askling","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026070605221782000_ref4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid arthritis and risk of malignant lymphoma: Is the risk still increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026070605221782000_ref5","doi-asserted-by":"crossref","first-page":"e001241","DOI":"10.1136\/rmdopen-2020-001241","article-title":"Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002\u20132017","volume":"6","author":"Singh","year":"2020","journal-title":"RMD Open"},{"key":"2026070605221782000_ref6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia."},{"key":"2026070605221782000_ref7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/14397595.2021.1879362","article-title":"Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: a retrospective, multicenter, case\u2013control study","volume":"32","author":"Kuramoto","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026070605221782000_ref8","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Campo","year":"2017"},{"key":"2026070605221782000_ref9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"2026070605221782000_ref10","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41379-019-0264-2","article-title":"Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases","volume":"32","author":"Satou","year":"2019","journal-title":"Mod Pathol"},{"key":"2026070605221782000_ref11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/10428194.2017.1369073","article-title":"Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression","volume":"59","author":"Tokuhira","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2026070605221782000_ref12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/14397595.2021.1899570","article-title":"Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: a retrospective, multicenter, descriptive study","volume":"32","author":"Takada","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026070605221782000_ref13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026070605221782000_ref14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.2005.044784","article-title":"Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis","volume":"65","author":"Franklin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2026070605221782000_ref15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026070605221782000_ref16","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3109\/10428194.2015.1022769","article-title":"Methotrexate-associated lymphoproliferative disorders: Management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal","volume":"56","author":"Inui","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026070605221782000_ref17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/rheumatology\/kex002","article-title":"Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate","volume":"56","author":"Saito","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026070605221782000_ref18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2008.03.009","article-title":"Immunodeficiency-associated lymphomas","volume":"22","author":"Tran","year":"2008","journal-title":"Blood Rev"},{"key":"2026070605221782000_ref19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026070605221782000_ref20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"key":"2026070605221782000_ref21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026070605221782000_ref22","doi-asserted-by":"crossref","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2026070605221782000_ref23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ."},{"key":"2026070605221782000_ref24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.semarthrit.2018.06.006","article-title":"On the origin of rheumatoid factors: Insights from analyses of variable region sequences","volume":"48","author":"Falkenburg","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2026070605221782000_ref25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026070605221782000_ref26","doi-asserted-by":"crossref","first-page":"345e5244","DOI":"10.1136\/bmj.e5244","article-title":"Elevated rheumatoid factor and long term risk of rheumatoid arthritis: A prospective cohort study","volume":"345","author":"Nielsen","year":"2012","journal-title":"Bmj."},{"key":"2026070605221782000_ref27","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s10067-023-06646-0","article-title":"Prevalence and factors associated with polypharmacy among patients with rheumatoid arthritis: a single-centre, cross-sectional study","volume":"42","author":"Miyake","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2026070605221782000_ref28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/mr\/road003","article-title":"Single-centre, cross-sectional study on the factors and reasons for non-vaccination among patients with rheumatoid arthritis","volume":"34","author":"Miyake","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026070605221782000_ref29","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20160792","article-title":"Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor","volume":"213","author":"Tan","year":"2016","journal-title":"J Exp Med"},{"key":"2026070605221782000_ref30","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/ard.60.11.1007","article-title":"Lymphomas complicating Sj\u00f6gren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells","volume":"60","author":"Mariette","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"2026070605221782000_ref31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026070605221782000_ref32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1573395511309010003","article-title":"Possible mechanisms of lymphoma development in Sj\u00f6gren's syndrome","volume":"9","author":"Dong","year":"2013","journal-title":"Curr Immunol Rev"},{"key":"2026070605221782000_ref33","doi-asserted-by":"crossref","first-page":"e3766","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf125\/65854327\/roaf125.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/543\/65854327\/roaf125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/543\/65854327\/roaf125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:23:07Z","timestamp":1783329787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/543\/8377967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf125","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,12]]}}}